Imedicus Limited 09592107 false 2023-06-01 2024-05-31 2024-05-31 The principal activity of the company is Medical services Digita Accounts Production Advanced 6.30.9574.0 true true 09592107 2023-06-01 2024-05-31 09592107 2024-05-31 09592107 core:CurrentFinancialInstruments core:WithinOneYear 2024-05-31 09592107 core:Non-currentFinancialInstruments core:AfterOneYear 2024-05-31 09592107 core:FurnitureFittingsToolsEquipment 2024-05-31 09592107 core:OtherPropertyPlantEquipment 2024-05-31 09592107 bus:SmallEntities 2023-06-01 2024-05-31 09592107 bus:AuditExemptWithAccountantsReport 2023-06-01 2024-05-31 09592107 bus:FilletedAccounts 2023-06-01 2024-05-31 09592107 bus:SmallCompaniesRegimeForAccounts 2023-06-01 2024-05-31 09592107 bus:RegisteredOffice 2023-06-01 2024-05-31 09592107 bus:CompanySecretaryDirector1 2023-06-01 2024-05-31 09592107 bus:Director2 2023-06-01 2024-05-31 09592107 bus:PrivateLimitedCompanyLtd 2023-06-01 2024-05-31 09592107 core:FurnitureFittingsToolsEquipment 2023-06-01 2024-05-31 09592107 core:OtherPropertyPlantEquipment 2023-06-01 2024-05-31 09592107 core:PlantMachinery 2023-06-01 2024-05-31 09592107 countries:AllCountries 2023-06-01 2024-05-31 09592107 2023-05-31 09592107 core:FurnitureFittingsToolsEquipment 2023-05-31 09592107 core:OtherPropertyPlantEquipment 2023-05-31 09592107 2022-06-01 2023-05-31 09592107 2023-05-31 09592107 core:CurrentFinancialInstruments core:WithinOneYear 2023-05-31 09592107 core:Non-currentFinancialInstruments core:AfterOneYear 2023-05-31 09592107 core:FurnitureFittingsToolsEquipment 2023-05-31 09592107 core:OtherPropertyPlantEquipment 2023-05-31 iso4217:GBP xbrli:pure

Registration number: 09592107

Imedicus Limited

Unaudited Filleted Abridged Financial Statements

for the Year Ended 31 May 2024

 

Imedicus Limited

Contents

Company Information

1

Abridged Balance Sheet

2

Notes to the Unaudited Abridged Financial Statements

3 to 5

 

Imedicus Limited

Company Information

Directors

Dr Soumendra Datta

Dr Hema Datta

Company secretary

Dr Soumendra Datta

Registered office

Charles Rippin & Turner
Middlesex House
130 College Road
Harrow
Middlesex
HA1 1BQ

Accountants

Charles Rippin & Turner
Chartered Accountants
Middlesex House
130 College Road
Harrow
Middlesex
HA1 1BQ

 

Imedicus Limited

(Registration number: 09592107)
Abridged Balance Sheet as at 31 May 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

334,373

192,982

Current assets

 

Cash at bank and in hand

 

27,440

45,045

Creditors: Amounts falling due within one year

(52,275)

(55,533)

Net current liabilities

 

(24,835)

(10,488)

Total assets less current liabilities

 

309,538

182,494

Creditors: Amounts falling due after more than one year

(8,033)

(11,414)

Accruals and deferred income

 

(5,000)

(3,941)

Net assets

 

296,505

167,139

Capital and reserves

 

Called up share capital

100

100

Retained earnings

296,405

167,039

Shareholders' funds

 

296,505

167,139

For the financial year ending 31 May 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 29 June 2024 and signed on its behalf by:
 

.........................................
Dr Soumendra Datta
Company secretary and director

 

Imedicus Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2024

1

General information

The company is a private company limited by share capital, incorporated in Engaland and Wales.

The address of its registered office is:
Charles Rippin & Turner
Middlesex House
130 College Road
Harrow
Middlesex
HA1 1BQ

The principal place of business is:
Perry House
Perry Lane
Langham
Colchester
CO4 5PH

These financial statements were authorised for issue by the Board on 29 June 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Imedicus Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2024

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Furniture, fittings, tools and equipment

25% Reducing balance

Plant and equipment

25% Reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Imedicus Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2024

Share based payments

The company operates an equity-settled, share-based compensation plan, under which the entity receives services from employees as consideration for equity instruments (options) of the entity. The fair value of the employee services received is measured by reference to the estimated fair value at the grant date of equity instruments granted and is recognised as an expense over the vesting period. The estimated fair value of the option granted is calculated using the Black Scholes option pricing model. The total amount expensed is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied.

The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2023 - 2).

4

Tangible assets

Furniture, fittings and equipment
 £

Other tangible assets
£

Total
£

Cost or valuation

At 1 June 2023

113,950

86,065

200,015

Additions

-

147,819

147,819

At 31 May 2024

113,950

233,884

347,834

Depreciation

At 1 June 2023

1,575

5,458

7,033

Charge for the year

1,210

5,218

6,428

At 31 May 2024

2,785

10,676

13,461

Carrying amount

At 31 May 2024

111,165

223,208

334,373

At 31 May 2023

112,375

80,607

192,982

5

Debtors

Debtors includes £Nil (2023 - £Nil) due after more than one year.